Mark Freedman, MD, MSc, HBSc, CSPQ, FANA, FAAN, FRCPC

Professor of Medicine in Neurology, University of Ottawa; Director, Multiple Sclerosis Research Unit, Ottawa Hospital; Senior Scientist, Ottawa Hospital Research Institute

Articles

Do We Finally Have a Useful “Sed Rate” for Multiple Sclerosis?

June 15, 2021

All agree that having a simple, standardized serum biomarker to measure disease activity would offer the greatest utility in treating a medical condition such as MS, which now has a variety of graded therapies available.